Premium
Chemotherapy of Burkitt's lymphoma
Author(s) -
Ziegler John L.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197212)30:6<1534::aid-cncr2820300619>3.0.co;2-6
Subject(s) - medicine , cyclophosphamide , chemotherapy , lymphoma , regimen , burkitt's lymphoma , clinical trial , surgery , therapeutic effect , complete remission , disease , gastroenterology , oncology
Results of treatment of 117 patients with Burkitt's lymphoma followed for a minimum of 18 months were analyzed. All patients were clinically staged and treated according to randomized clinical trials. Sixteen patients (14%) died within the first week of treatment of causes related to widespread tumor. Ninety‐five of the remaining 101 evaluable patients achieved complete remission (95%), while six had partial responses and eventually died. The frequency of relapse was significantly lower in patients with localized tumors (39%) as compared to patients with generalized disease (70%), but was unaffected by the intensity of the initial therapeutic regimen. Patients who developed early relapse (within 10 weeks of first treatment) had a less favorable prognosis than patients who relapsed beyond this period. Preliminary results of a current immunotherapeutic trial using BCG following cyclophosphamide‐induced remission suggest a protective effect of this treatment on the development of extradural relapse. These results provide guidelines for future therapeutic approaches which are discussed.